Pharmacopé: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Pharmacopé
Largest movements
- Current investments +€25,000
up €25,000 (+20.0%), from €125,000 to €150,000
- Cash -€22,878
down €22,878 (-30.8%), from €74,371 to €51,493
mainly Current investments (-€25,000) and Net result for the year (-€931)
No liability line moved by more than 1% of the balance sheet total.
- Gross operating margin -€16,423
down €16,423, from €15,661 to -€761
- Taxes -€5,393
down €5,393 (-87.5%), from €6,160 to €767
- Financial income -€1,075
down €1,075 (-32.0%), from €3,365 to €2,290
- Other operating charges -€201
down €201 (-13.4%), from €1,500 to €1,299
- Depreciation -€158
down €158 (-36.7%), from €431 to €273
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €206,860 | €208,146 | +€1,286 | +0.6% |
| Fixed assets | 21/28 | €1,273 | €1,000 | -€273 | -21.4% |
| Tangible fixed assets | 22/27 | €273 | - | -€273 | |
| Plant, machinery and equipment | 23 | €273 | - | -€273 | |
| Financial fixed assets | 28 | €1,000 | €1,000 | = | 0.0% |
| Current assets | 29/58 | €205,588 | €207,146 | +€1,559 | +0.8% |
| Amounts receivable within one year | 40/41 | €4,572 | €5,066 | +€494 | +10.8% |
| Trade receivables | 40 | €454 | €832 | +€378 | +83.3% |
| Other amounts receivable | 41 | €4,119 | €4,234 | +€115 | +2.8% |
| Current investments | 50/53 | €125,000 | €150,000 | +€25,000 | +20.0% |
| Cash at bank and in hand | 54/58 | €74,371 | €51,493 | -€22,878 | -30.8% |
| Deferred charges and accrued income | 490/1 | €1,644 | €587 | -€1,056 | -64.3% |
| Total equity and liabilities | 10/49 | €206,860 | €208,146 | +€1,286 | +0.6% |
| Equity | 10/15 | €202,912 | €201,981 | -€931 | -0.5% |
| Contributions | 10/11 | €18,550 | €18,550 | = | 0.0% |
| Reserves | 13 | €168,855 | €168,855 | = | 0.0% |
| Distributable reserves | 133 | €168,855 | €168,855 | = | 0.0% |
| Profit (loss) carried forward | 14 | €15,507 | €14,576 | -€931 | -6.0% |
| Amounts payable | 17/49 | €3,948 | €6,165 | +€2,217 | +56.2% |
| Amounts payable within one year | 42/48 | €3,948 | €6,165 | +€2,217 | +56.2% |
| Trade debts | 44 | €60 | €652 | +€592 | +985% |
| Suppliers | 440/4 | €60 | €652 | +€592 | +985% |
| Taxes, remuneration and social security | 45 | €1,300 | €1,800 | +€500 | +38.5% |
| Taxes | 450/3 | €1,300 | €1,800 | +€500 | +38.5% |
| Other amounts payable | 47/48 | €2,588 | €3,713 | +€1,125 | +43.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €431 | €273 | -€158 | -36.7% |
| Other operating charges | 640/8 | €1,500 | €1,299 | -€201 | -13.4% |
| Gross operating margin | 9900 | €15,661 | -€761 | -€16,423 | |
| Operating profit (loss) | 9901 | €13,730 | -€2,333 | -€16,063 | |
| Financial income | 75/76B | €3,365 | €2,290 | -€1,075 | -32.0% |
| Recurring financial income | 75 | €3,365 | €2,290 | -€1,075 | -32.0% |
| Financial charges | 65/66B | €136 | €121 | -€15 | -11.1% |
| Recurring financial charges | 65 | €136 | €121 | -€15 | -11.1% |
| Profit (loss) for the period before taxes | 9903 | €16,959 | -€164 | -€17,123 | |
| Income taxes | 67/77 | €6,160 | €767 | -€5,393 | -87.5% |
| Profit (loss) for the period | 9904 | €10,799 | -€931 | -€11,730 | |
| Profit (loss) for the period to be appropriated | 9905 | €10,799 | -€931 | -€11,730 |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 19 October 2026 via checked.be.